Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care LLC ("Linden Care" or the "Company"), a leading provider of comprehensive specialty pharmacy solutions to the pain management industry and a portfolio company of BelHealth Investment Partners, announced a new national contract under its Comprehensive Hub Solutions Program (the "Program").

Linden Care's Program provides distribution and access support to manufacturers for pain medications. With a presence on each coast, best in class compliance practices and deep relationships in the pain industry, Linden Care is the specialty pharmacy of choice for pain pharmaceutical manufacturers.

Key to Linden Care's success is the ability to provide solutions for today's complex pain therapies requiring Risk Evaluation and Mitigation Strategies (REMS) such as transmucosal immediate release fentanyls (TIRF) and extended release opioids. Linden Care has developed best-in-class Standard Operating Procedures (SOP's) around physician/patient vetting, identifying diversion activity, managing Patient Assistance Programs (PAPs) and manufacturer coupons, enhanced reporting and overall program integrity.

Pain management is a factor across all major disease states including: Oncology, Rheumatoid Arthritis (RA), Crohn's and neurological disorders (MS). As the country's largest specialty pharmacy focused on pain management, Linden Care is well positioned to continue growing its base of pain manufacturer customers.

Glenn Bortnick, Vice President of Pharma Relations said, "We are very excited about the acceptance and growth of our new Program. With our presence on each coast and unparalleled support services, Linden Care is uniquely positioned to continue gaining market share and growing our hub solutions program."


Linden Care LLC


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Global healthcare consulting revenues grow in 2018 to pass US$10bn